GE

Seven global biopharmas form neuroscience consortium

Wednesday, June 20, 2012 02:56 PM

Seven global biopharmaceutical companies have formed the Massachusetts Neuroscience Consortium, which will fund pre-clinical neuroscience at Massachusetts academic and research institutions. Participants include Abbott, Biogen Idec, EMD Serono, Janssen Research & Development, Merck, Pfizer and Sunovion Pharmaceuticals.

More... »

AstraZeneca, Rigel ink worldwide license for new asthma treatment

Wednesday, June 20, 2012 11:26 AM

Biopharmaceutical companies AstraZeneca and Rigel Pharmaceuticals have signed an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signaling being investigated as a treatment for moderate to severe chronic asthma. 

More... »

AC Immune, Genentech form second antibody collaboration for Alzheimer's

Monday, June 18, 2012 03:03 PM

Swiss-based biopharmaceutical company AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, a member of the Roche Group, for research, development and commercialization of AC Immune's anti-Tau antibodies for the potential treatment of Alzheimer's disease and other neurodegenerative diseases.

More... »

HGS sets July 16 deadline for acquisition proposals

Friday, June 15, 2012 02:09 PM

In connection with its ongoing strategic alternative review process, Human Genome Sciences (HGS) has set a bid date of July 16, 2012, for the submission of definitive proposals to acquire all outstanding common shares of HGS.

More... »

Upsher-Smith to acquire U.K.-based Proximagen

Thursday, June 14, 2012 12:33 PM

Upsher-Smith Laboratories, a privately-owned specialty pharmaceutical company of Maple Grove, Minn., has agreed to acquire Proximagen Group, a European biotech focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation. Upsher-Smith intends to retain operations in Cambridge and London, England.

More... »

First MDS consortium to conduct trials and research to improve patient outcomes

Thursday, June 14, 2012 09:23 AM

Taussig Cancer Institute at Cleveland Clinic will participate in an unprecedented, six-institution consortium designed to conduct clinical trials and research to improve outcomes for patients with myelodysplastic syndrome (MDS).

More... »

GSK extends tender offer for HGS shares

Monday, June 11, 2012 09:49 AM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on Friday, June 29, 2012. The tender offer was previously scheduled to expire at 12:00 midnight EST, at the end of the day on June 7, 2012.

More... »

Generex touts positive AE37 cancer vaccine technology

Friday, June 8, 2012 11:56 AM

Generex Biotechnology reported promising technology and clinical results from its on-going phase II trial of the AE37 breast cancer vaccine being developed by its subsidiary Antigen Express.

More... »

Complete Genomics to restructure, cut 55 jobs

Wednesday, June 6, 2012 01:19 PM

Complete Genomics, a whole human genome sequencing company based in Mountain View, Calif., is taking steps to reduce cash consumption and has engaged Jefferies & Company to assist it in exploring strategic alternatives.

More... »

Emergent BioSolutions secures funding from BARDA for anthrax vaccine

Monday, June 4, 2012 11:33 AM

Emergent BioSolutions of Rockville, Md., has reached an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a non-interference study to be used to support a post-exposure prophylaxis (PEP) indication for BioThrax, an adsorbed anthrax vaccine.

More... »